1.    Mak KY, Rajapaksha IG, Angus PW, Herath CB. The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders. Curr Gene Ther. 2017;17(1):4-16.
2.    Samson A, Bentham MJ, Scott K, Nuovo G, Bloy A, Appleton E, et al. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut. 2018;67(3):562-573.
3.    Kirschner J, Cathomen T. Gene Therapy for Monogenic Inherited Disorders: Opportunities and Challenges. Dtsch Arztebl Int. 2020;117(51-52): 878–885.
4.    Zhan W, Muhuri M, Tai PWL, Gao G. Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens? Front Immunol. 2021;12:673699.
5.    Montaño-Samaniego M, Bravo-Estupiñan DM, Méndez-Guerrero O, Alarcón-Hernández E, Ibáñez-Hernández M. Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters. Front Oncol. 2020;10:605380.
6.    Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9(1):GE01-GE6.
7.    Foldvari M, Chen DW, Nafissi N, Calderon D, Narsineni L, Rafiee A. Non-viral gene therapy: Gains and challenges of non-invasive administration methods. J Control Release. 2016;240:165-190.
8.    O’Reilly M, Jambou R, Rosenthal E, Montgomery M, Hassani M, Gargiulo L, et al. The national institutes of health oversight of human gene transfer research: Enhancing science and safety. Adv Exp Med Biol. 2015:871:31-47.
9.    Gantenbein B, Tang S, Guerrero J, Higuita-Castro N, Salazar-Puerta AI, Croft AS, et al. Non-viral gene delivery methods for bone and joints. Front Bioeng Biotechnol. 2020;8: 598466.
10.    Deng W, Chen W, Clement S, Guller A, Zhao Z, Engel A, et al. Controlled gene and drug release from a liposomal delivery platform triggered by X-ray radiation. Nature Communications. 2018;9(1):2713.
11.    Nakamura T, Akita H, Yamada Y, Hatakeyama H, Harashima H. A Multifunctional envelope-type nanodevice for use in nanomedicine: Concept and applications. Acc Chem Res. 2012;45(7):1113-1121.
12.    Kamiya H, Akita H, Harashima H. Pharmacokinetic and pharmacodynamic considerations in gene therapy. Drug Discov Today. 2003;8(21):990-996.
13.    Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release. 2004;98(2):317-323.
14.    Hatakeyama H, Akita H, Harashima H. The Polyethyleneglycol Dilemma: Advantage and Disadvantage of PEGylation of Liposomes for Systemic Genes and Nucleic Acids Delivery to Tumors. Biol Pharm Bull. 2013;36(6):892-899.
15.    Kogure K, Akita H, Yamada Y, Harashima H. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. Adv Drug Deliv Rev.. 2008;60(4):559-71.
16.    Puras G, Martínez-Navarrete G, Mashal M, Zárate J, Agirre M, Ojeda E, et al. Protamine/DNA/Niosome ternary nonviral vectors for gene delivery to the retina: The role of protamine. Mol Pharm. 2015;12(10):3658-3671.
17.    Motta S, Brocca P, Favero ED, Rondelli V, Cantù L, Amici A, et al. Nanoscale structure of protamine/DNA complexes for gene delivery. App Phys Lett. 2013;102(5):053703.
18.    Kuzmich A, Rakitina O, Didych D, Potapov V, Zinovyeva M, Alekseenko I, et al. Novel histone-based DNA carrier targeting cancer-associated fibroblasts. Polymers. 2020;12(8): 1695.
19.    He H, Ye J, Liu E, Liang Q, Liu Q, Yang VC. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide. J Control Release. 2014;193:63-73.
20.    Xia H, Gao X, Gu G, Liu Z, Zeng N, Hu Q, et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials. 2011;32(36):9888-9898.
21.    Park YJ, Liang JF, Ko KS, Kim SW, Yang VC. Low molecular weight protamine as an efficient and nontoxic gene carrier: In vitro study. J Gene Med. 2003;5(8):700-711.
22.    Jafari M, Soltani M, Naahidi S, Karunaratne DN, Chen P. Nonviral approach for targeted nucleic acid delivery. Curr Med Chem. 2012;19(2):197-208.
23.    Zarei H, Malaekeh-Nikouei B, Ramezani M, Soltani F. Multifunctional peptides based on low molecular weight protamine (LMWP) in the structure of polyplexes and lipopolyplexes: Design, preparation and gene delivery characterization. Journal of Drug Delivery Science and Technology. 2021;62:102422.
24.    Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19(14):1978-1985.
25.    Cheng L, Huang FZ, Cheng LF, Zhu YQ, Hu Q, Li L, et al. GE11-modified liposomes for non-small cell lung cancer targeting: Preparation, ex vitro and in vivo evaluation. Int J Nanomedicine. 2014;9:921-935.
26.    Niesner U, Halin C, Lozzi L, Günthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem. 2002;13(4):729-736.
27.    Dos Santos T, Varela J, Lynch I, Salvati A, Dawson KAJPo. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS One. 2011;6(9):e24438.
28.    Song Y, Shi Y, Zhang L, Hu H, Zhang C, Yin M, et al. Oral delivery system for low molecular weight protamine-dextran-poly(lactic-co-glycolic acid) carrying exenatide to overcome the mucus barrier and improve intestinal targeting efficiency. Nanomedicine. 2019;14(8):989-1009.
29.    Welser K, Campbell F, Kudsiova L, Mohammadi A, Dawson N, Hart SL, et al. Gene delivery using ternary lipopolyplexes incorporating branched cationic peptides: The role of peptide sequence and branching. Mol Pharm. 2013;10(1):127-141.
30.    Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377(Pt 1):159-169.
31.    Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacological reviews. Pharmacol Rev. 2006;58(1):32-45.
32.    Tang Q, Cao B, Wu H, Cheng G. Cholesterol-peptide hybrids to form liposome-like vesicles for gene delivery. PLoS One. 2013;8(1):e54460.
33.    Nakamura K, Yamashita K, Itoh Y, Yoshino K, Nozawa S, Kasukawa H. Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods. Biochim Biophys Acta. 2012;1818(11):2801-2807.
34.    Sabourian P, Yazdani G, Ashraf SS, Frounchi M, Mashayekhan S, Kiani S, et al. Effect of physico-chemical properties of nanoparticles on their intracellular uptake. Int J Mol Sci. 2020;21(21):8019.